Last reviewed · How we verify
Tocilizumab Injection
Tocilizumab Injection is an interleukin-6 receptor antagonist that blocks the action of interleukin-6, a cytokine involved in inflammation.
Tocilizumab Injection is an interleukin-6 receptor antagonist that blocks the action of interleukin-6, a cytokine involved in inflammation. Used for Rheumatoid arthritis, Juvenile idiopathic arthritis.
At a glance
| Generic name | Tocilizumab Injection |
|---|---|
| Also known as | ROACTEMRA, Actemra, ACTEMRA® |
| Sponsor | Abderrahmane Mami Hospital |
| Drug class | IL-6 receptor antagonist |
| Target | IL-6R |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
By blocking interleukin-6, tocilizumab reduces inflammation and has anti-inflammatory effects. This mechanism is particularly useful in treating conditions characterized by excessive inflammation, such as rheumatoid arthritis.
Approved indications
- Rheumatoid arthritis
- Juvenile idiopathic arthritis
Common side effects
- Increased risk of infections
- Neutropenia
- Thrombocytopenia
- Hypersensitivity reactions
Key clinical trials
- A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) (PHASE1, PHASE2)
- Part B- G1X-CGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease (PHASE1, PHASE2)
- Tocilizumab in Lung Transplantation (PHASE2)
- Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma (PHASE2)
- Phase II Interventional Study Evaluating Efficacy and Safety of Secukinumab in Active Severe Takayasu Patients (PHASE2)
- Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission (NA)
- Neutralizing Interleukin (IL)-6 (PHASE2)
- ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tocilizumab Injection CI brief — competitive landscape report
- Tocilizumab Injection updates RSS · CI watch RSS
- Abderrahmane Mami Hospital portfolio CI